-
公开(公告)号：US20230277442A1
公开(公告)日：2023-09-07
申请号：US18174043
申请日：2023-02-24
发明人： Tomoyuki IGAWA , Chifumi MORIYAMA
CPC分类号： A61K9/0019 , A61K39/39591 , A61K47/12 , A61K47/18 , A61K47/183 , A61K47/26 , A61K9/19 , A61K39/395
摘要： The present inventors discovered that a significant stabilization effect was achieved by using an acidic amino acid, aspartic acid or glutamic acid as a counter ion species in histidine buffer or tris(hydroxymethyl)aminomethane, specifically by using histidine-aspartate buffer or histidine-glutamate buffer, or tris(hydroxymethyl)aminomethane-aspartate or tris(hydroxy-methyl) aminomethane-glutamate as a buffer. The present inventors also discovered that a significant stabilization effect was achieved by using an acidic amino acid, aspartic acid or glutamic acid, as a counter ion species to a basic amino acid such as arginine, specifically by using arginine-aspartate or arginine-glutamate.
-
公开(公告)号：US20220089715A1
公开(公告)日：2022-03-24
申请号：US17494199
申请日：2021-10-05
发明人： Tomoyuki IGAWA , Atsuhiko MAEDA , Kenta HARAYA , Tatsuhiko TACHIBANA , Yuki IWAYANAGI , Yuji HORI , Genki NAKAMURA , Masaru MURAOKA
摘要： One nonexclusive aspect provides molecules further improved from antibodies that can bind to antigens in an ion concentration-dependent manner. An alternative nonexclusive aspect provides safe and more advantageous Fc region variants that have decreased binding to pre-existing ADA. An alternative nonexclusive aspect provides novel IL-8 antibodies that are superior as pharmaceuticals.
-
公开(公告)号：US20210221875A1
公开(公告)日：2021-07-22
申请号：US17058961
申请日：2019-05-30
发明人： Hidetomo KITAMURA , Maiko HOSHINO , Yang SUN , Taichi KURAMOCHI , Wenjie TU , Tomoyuki IGAWA , Naoka HIRONIWA , Yuki NOGUCHI
IPC分类号： C07K16/18
摘要： The present invention provides a polypeptide comprising an antigen binding domain which binds to an antigen present in cartilage tissue, and also provides use of the polypeptide. The polypeptide of the invention is useful for penetrating and/or retaining a desired substance in the cartilage tissue for a long period. The present invention further relates to a polypeptide comprising (i) an antigen binding domain which binds to a molecule in a cartilage tissue, and (ii) a carrying moiety having an inhibiting domain that inhibits the antigen binding activity of the antigen binding domain, and having a longer half-life than that of the antigen binding domain existing alone, and a pharmaceutical composition comprising the polypeptide. The present invention further relates to methods for producing and screening for the polypeptide.
-
公开(公告)号：US20180244805A1
公开(公告)日：2018-08-30
申请号：US15963221
申请日：2018-04-26
发明人： Junichi NEZU , Atsushi NARITA , Takahiro ISHIGURO , Mika SAKURAI , Hirotake SHIRAIWA , Naoka HIRONIWA , Tomoyuki IGAWA , Yumiko KAWAI
CPC分类号： C07K16/468 , A61K39/395 , A61K2039/505 , C07K16/28 , C07K16/2809 , C07K16/30 , C07K16/303 , C07K16/46 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2317/524 , C07K2317/526 , C07K2317/565 , C07K2317/567 , C07K2317/71 , C07K2317/73 , C07K2317/92 , C07K2317/94 , C12N5/10 , C12N15/09
摘要： Novel multispecific antigen-binding molecules maintaining excellent cellular cytotoxicity and high stability, which comprise a domain that contains an antibody variable region having glypican 3-binding activity and a domain that contains an antibody variable region having T-cell receptor complex-binding activity, were discovered. Since the molecules of the present invention show a strong cytotoxicity against cells and tissues expressing glypican 3, it is possible to produce novel pharmaceutical compositions for treating or preventing various cancers.
-
公开(公告)号：US20150315278A1
公开(公告)日：2015-11-05
申请号：US14629967
申请日：2015-02-24
发明人： Tomoyuki IGAWA , Taichi Kuramochi , Hirotake Shiraiwa , Hiroyuki Tsunoda , Tatsuhiko Tachibana , Takahiro Ishiguro
CPC分类号： C07K16/2863 , A61K2039/505 , A61K2039/545 , C07K16/18 , C07K16/30 , C07K16/303 , C07K2317/14 , C07K2317/56 , C07K2317/73 , C07K2317/732 , C07K2317/92 , C07K2317/94 , C12N15/8258
摘要： A method of modulating the plasma half-life of anti-glypican 3 antibody, a pharmaceutical composition comprising as an active ingredient the anti-glypican 3 antibody that has a plasma half-life that has been modulated, a method of preparing the anti-glypican 3 antibody and a pharmaceutical composition comprising the anti-glypican 3 antibody as an active ingredient are provided. Disclosed is a method of modulating the plasma half-life of anti-glypican 3 antibody by modifying an amino acid residue that is exposed on the surface of the anti-glypican 3 antibody; and anti-glypican 3 antibody that has a plasma half-life that has been modulated by amino acid residue modification, a pharmaceutical composition comprising as an active ingredient the anti-glypican 3 antibody, and a method of preparing the anti-glypican 3 antibody and producing a pharmaceutical composition comprising the anti-glypican 3 antibody as an active ingredient.
摘要翻译： 调节抗磷脂酰肌醇蛋白聚糖3抗体的血浆半衰期的方法，一种药物组合物，其包含具有调节的血浆半衰期的抗磷脂酰肌醇蛋白聚糖3抗体作为活性成分，制备抗磷脂酰肌醇蛋白聚糖的方法 提供了包含抗磷脂酰肌醇蛋白聚糖3抗体作为活性成分的药物组合物。 公开了通过改变暴露于抗磷脂酰肌醇蛋白聚糖3抗体表面的氨基酸残基来调节抗磷脂酰肌醇蛋白聚糖3抗体的血浆半衰期的方法; 和具有通过氨基酸残基修饰调节的血浆半衰期的抗磷脂酰肌醇蛋白聚糖3抗体，包含作为活性成分的磷脂酰肌醇蛋白聚糖3抗体的药物组合物，以及制备抗磷脂酰肌醇蛋白聚糖3抗体的方法和 制备包含抗磷脂酰肌醇蛋白聚糖3抗体作为活性成分的药物组合物。
-
公开(公告)号：US20130295612A1
公开(公告)日：2013-11-07
申请号：US13924957
申请日：2013-07-25
发明人： Tomoyuki IGAWA , Taichi Kuramochi , Hirotake Shiraiwa , Hiroyuki Tsunoda , Tatsuhiko Tachibana , Takahiro Ishiguro
IPC分类号： C07K16/18
CPC分类号： C07K16/2863 , A61K2039/505 , A61K2039/545 , C07K16/18 , C07K16/30 , C07K16/303 , C07K2317/14 , C07K2317/56 , C07K2317/73 , C07K2317/732 , C07K2317/92 , C07K2317/94 , C12N15/8258
摘要： A method of modulating the plasma half-life of anti-glypican 3 antibody, a pharmaceutical composition comprising as an active ingredient the anti-glypican 3 antibody that has a plasma half-life that has been modulated, a method of preparing the anti-glypican 3 antibody and a pharmaceutical composition comprising the anti-glypican 3 antibody as an active ingredient are provided. Disclosed is a method of modulating the plasma half-life of anti-glypican 3 antibody by modifying an amino acid residue that is exposed on the surface of the anti-glypican 3 antibody; and anti-glypican 3 antibody that has a plasma half-life that has been modulated by amino acid residue modification, a pharmaceutical composition comprising as an active ingredient the anti-glypican 3 antibody, and a method of preparing the anti-glypican 3 antibody and producing a pharmaceutical composition comprising the anti-glypican 3 antibody as an active ingredient.
摘要翻译： 调节抗磷脂酰肌醇蛋白聚糖3抗体的血浆半衰期的方法，一种药物组合物，其包含具有调节的血浆半衰期的抗磷脂酰肌醇蛋白聚糖3抗体作为活性成分，制备抗磷脂酰肌醇蛋白聚糖的方法 提供了包含抗磷脂酰肌醇蛋白聚糖3抗体作为活性成分的药物组合物。 公开了通过改变暴露于抗磷脂酰肌醇蛋白聚糖3抗体表面的氨基酸残基来调节抗磷脂酰肌醇蛋白聚糖3抗体的血浆半衰期的方法; 和具有通过氨基酸残基修饰调节的血浆半衰期的抗磷脂酰肌醇蛋白聚糖3抗体，包含作为活性成分的磷脂酰肌醇蛋白聚糖3抗体的药物组合物，以及制备抗磷脂酰肌醇蛋白聚糖3抗体的方法和 制备包含抗磷脂酰肌醇蛋白聚糖3抗体作为活性成分的药物组合物。
-
公开(公告)号：US20240018503A1
公开(公告)日：2024-01-18
申请号：US18448263
申请日：2023-08-11
发明人： Tomoyuki IGAWA , Miho FUNAKI , Hiroyuki MIYASHITA
CPC分类号： C12N9/644 , A61P7/04 , A61K38/4846 , C07K16/36 , C12Y304/21022 , C07K2319/30
摘要： The present invention provides a method for improving or controlling the plasma half-life and/or bio-availability of blood coagulation factor IX (FIX), the method comprising modifying the GLA domain. Examples of such modifications include: (i) non-covalent bonding of a GLA-domain-recognizing antibody or an antibody fragment thereof to the GLA domain; (ii) reduced number of Gla residues in the GLA domain, in comparison to that of a native FIX; (iii) either or both of deletion of one or more glutamic acid residues in the GLA domain and substitution of one or more glutamic acid residues in the GLA domain with another amino acid; and (iv) deletion of a part or all of the GLA domain. The present invention also provides a FIX with improved pharmacokinetics which carries such modifications, a pharmaceutical composition containing the FIX as an active ingredient, a method for producing the FIX, and such.
-
8.发明公开公开(公告)号：US20240002836A1
公开(公告)日：2024-01-04
申请号：US18156138
申请日：2023-01-18
发明人： Tomoyuki IGAWA , Shinya ISHII , Atsuhiko MAEDA , Takashi NAKAI
CPC分类号： C12N15/1037 , C07K16/244 , C07K16/248 , A61K2039/505 , A61K39/145 , C07K16/2866 , G01N33/6854 , A61K39/12
摘要： The present inventors discovered that antibodies having weaker antigen-binding activity at the early endosomal pH in comparison with that at the pH of plasma are capable of binding to multiple antigen molecules with a single antibody molecule, have long half-lives in plasma, and have improved durations of time in which they can bind to antigen.
-
公开(公告)号：US20230058982A1
公开(公告)日：2023-02-23
申请号：US17788998
申请日：2019-12-27
发明人： Hitoshi KATADA , Kanako TATSUMI , Kanako ATSUMI , Shun SHIMIZU , Masaki KAMIMURA , Yasunori KOMORII , Yuji HORI , Tomoyuki IGAWA , Hiroki KAWAUCHI , Hiroaki SUSUMU
摘要： The present disclosure provides anti-CTLA-4 antibodies and methods of producing and using the antibodies. The present disclosure also provides nucleic acids encoding the anti-CTLA-4 antibodies and host cells containing the nucleic acids. Furthermore, the present disclosure provides polypeptides containing a variant Fc region and methods of producing and using the polypeptides.
-
公开(公告)号：US20220401557A1
公开(公告)日：2022-12-22
申请号：US17847909
申请日：2022-06-23
发明人： Tomoyuki IGAWA , Naoka HIRONIWA , Hiroki KAWAUCHI
IPC分类号： A61K39/395 , A61K47/42 , C07K16/28 , C07K16/32 , C07K19/00 , C12N15/09 , C07K14/00 , C07K7/00 , A61K47/50 , A61K51/10 , A61K47/68 , A61P35/00 , C12P21/00
摘要： A multiple antigen-binding molecule fusion molecule containing a multiple antigen-binding molecule (α) having an immune cell antigen-binding region and a cancer antigen-binding region, a cancer tissue-specific protease-cleavable linker (β), and a masking molecule (γ) containing a polypeptide having the amino acid sequence QDGNE, in which the multiple antigen-binding molecule (α) and the masking molecule (γ) are linked via the cancer tissue-specific protease-cleavable linker (β).
-
-
-
-
-
-
-
-
-
搜索结果
57 条记录 (耗时 0.032 秒)
